In this research, a design method for the graded triply periodic minimal surface (TPMS) structures with lightweight, high-strength, and high sound absorption properties is proposed. The graded TPMS structures are controlled by linear, quadratic, and sine functions. Uniform TPMS and graded TPMS were manufactured by laser powder bed fusion (LPBF) with AlSi7Mg powder, and an acoustic impedance tube test, compression test, and digital image correlation (DIC) test were ap-plied to obtain the sound absorption and compression properties. The sound absorption coefficient of a uniform Gyroid increases as the number of layers and surface thickness increase, and it in-creases as element size decreases. The sound absorption peak shifts to low frequencies as the number of layers increases. The sound absorption property of Type-Ⅰ graded TPMS is superior to the Type-Ⅱ, and the G-LinearⅠ has the highest sound absorption properties among the three functions. It reveals that the graded TPMS has superior sound absorption performance at low and medium frequencies. The compression and DIC results of graded TPMS also show excellent mechanical properties and energy absorption characteristics.

The Omicron EG.5 lineage of SARS-CoV-2 is currently on a trajectory to become a dominant strain. This phase 2 study aims to evaluate the immunogenicity of SCTV01E-2, a tetravalent protein vaccine, with a specific emphasis on its effectiveness against Omicron EG.5, comparing it with its progenitor vaccine, SCTV01E (NCT05933512). As of September 12, 2023, 429 participants aged ≥18 years were randomized to SCTV01E (N=215) or SCTV01E-2 (N=214) groups. Both vaccines showed increases in neutralizing antibody (nAb) against Omicron EG.5, with a 5.7-fold increase and a 9.0-fold increase in SCTV01E and SCTV01E-2 groups 14 days post-vaccination, respectively. The predetermined statistical endpoints were achieved, showing that the geometric mean titer (GMT) of nAb and the seroresponse rate (SRR) against Omicron EG.5 were significantly higher in the SCTV01E-2 group compared to SCTV01E. Additionally, SCTV01E and SCTV01E-2 induced a 5.5-fold and a 5.9-fold increase of nAb against XBB.1, respectively. Reactogenicity was generally mild and transient. No vaccine related SAEs, AESIs or deaths were reported. In summary, SCTV01E-2 elicited robust neutralizing responses against Omicron EG.5 and XBB.1 without safety concerns, underlining its potential as a versatile COVID-19 vaccine against SARS-CoV-2 variants.